Answer 6 quick questions — mapped to the criteria licensed Boao Lecheng programs actually publish (C-peptide, diabetes duration, HbA1c, age, exclusions). Get an instant verdict, no email required to see it.
Eligibility is the treating physician's call against each licensed program's published criteria. For diabetes programs the typical ranges are: measurable residual beta-cell function (C-peptide), disease duration usually 1–15 years, HbA1c 7.5–12%, age 18–70, and no active cancer, severe CVD, active infection or pregnancy. The only way to know for your case is a formal medical review of your records — that's what the free review above is for.
The Boao Lecheng International Medical Tourism Pilot Zone in Hainan is China's designated zone for translating new biomedical technologies into clinical care. As of March 2026 it had approved 21 cell and gene therapy projects across five batches, including a type 2 diabetes umbilical-cord MSC protocol published at about ¥58,000 per injection (3-injection course).
Citizens of 86 countries can enter Hainan visa-free. For treatment stays, the S1/S2 medical visa route is also available with financial and medical documentation. Pilot hospitals run international departments with English-speaking coordinators.
As of 2026, no stem cell product for diabetes holds NMPA marketing approval. Licensed commercial programs operate on the Boao Lecheng pilot-zone clinical-translation track — a separate, regulated pathway from national product approval.